Related Experiment Video
Updated: Aug 2, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Sumatriptan blocks neurogenic inflammation in the peripheral nerve trunk
1University of Calgary, Department of Clinical Neurosciences, AB, Canada.
Neurology
|January 1, 1994
Summary
Sumatriptan, a migraine treatment, stops neurogenic inflammation by preventing vasodilation. This action occurs independently of vasoconstriction or altered blood flow, offering new insights into migraine mechanisms.
Area of Science:
- Pharmacology
- Neuroscience
- Inflammation Research
Background:
- Migraine headaches are often linked to neurogenic inflammation.
- Sumatriptan is a 5-HT1D receptor agonist used to treat migraines.
- Neurogenic inflammation involves vasodilation mediated by nerve activation.
Purpose of the Study:
- To investigate the mechanism by which sumatriptan prevents neurogenic inflammation.
- To determine if sumatriptan's action involves vasoconstriction or altered arteriovenous shunt flow.
Main Methods:
- A rat sciatic nerve model of neurogenic inflammation was used.
- Capsaicin was applied to the sciatic epineurium to induce inflammation.
- Intraperitoneal sumatriptan was administered to test its effects.
Main Results:
- Sumatriptan effectively prevented capsaicin-induced hyperemia (vasodilation).
- Sumatriptan did not cause pretreatment vasoconstriction.
- Sumatriptan did not alter arteriovenous (AV) shunt flow.
Conclusions:
- Sumatriptan prevents neurogenic vasodilation through a mechanism distinct from vasoconstriction.
- The findings suggest sumatriptan's anti-migraine effect is not solely due to direct vasoconstriction.
- Further research into sumatriptan's non-vasoconstrictive pathways is warranted.
Related Concept Videos
01:28Drugs Acting on Autonomic Ganglia: Blockers
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
01:29Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:24Local Anesthetics: Differential Sensitivity of Nerve Fibers
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...